BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32.

波士顿，2024年2月28日/PRNewswire/--今天，正在构建细胞编程和生物安全领先平台的银杏生物工程（NYSE:DNA）宣布收购Patch Biosciences，该公司为序列设计构建了一个AI平台，该平台能够实现更有效，更具体和更持久的遗传药物，并得到了卡斯丁资本安德烈森·霍洛维茨（a16z）生物+健康公司的支持，和S32。

The acquisition is intended to strengthen Ginkgo's Gene Therapy Services, Cell Therapy Services, and RNA Therapeutics Services..

此次收购旨在加强银杏的基因治疗服务、细胞治疗服务和RNA治疗服务。。

Ginkgo does not have a product portfolio or drug pipeline. Instead, Ginkgo provides R&D services to customers who are looking to innovate across industries, including many world-class partners in biopharma. Ginkgo will incorporate Patch's machine learning models and downstream assays into its existing platform, making new capabilities in synthetic promoter and untranslated region (UTR) engineering available to partners.

银杏没有产品组合或药物管道。相反，银杏为寻求跨行业创新的客户提供研发服务，包括许多世界级的生物制药合作伙伴。银杏将把Patch的机器学习模型和下游分析纳入其现有平台，为合作伙伴提供合成启动子和非翻译区（UTR）工程的新功能。

Additionally, Patch's validated muscle promoters and robust RNA UTRs complement Ginkgo's circular RNA and promoter screening platform technology, which is already accelerating customer program progress. .

此外，Patch经过验证的肌肉启动子和强大的RNA UTR补充了银杏的环状RNA和启动子筛选平台技术，这已经加速了客户计划的进展。。

Jason Kelly, CEO and co-founder of Ginkgo Bioworks: 'Patch has built an excellent team and platform which we are excited to welcome to Ginkgo. Integrating Patch's capabilities, libraries, and datasets is immediately valuable to our on-going programs and augments the genetic medicine toolkit we have built for our customers.

Ginkgo Bioworks的首席执行官兼联合创始人杰森·凯利（JasonKelly）说：“Patch建立了一个优秀的团队和平台，我们很高兴欢迎来到Ginkgo。集成Patch的功能、库和数据集对我们正在进行的项目非常有价值，并增强了我们为客户构建的遗传医学工具包。

We want to bring a unified R&D experience to our customers and offering integrated services that include specialized assets like Patch's allow our customers to tap into a broader-than-ever capability set.'.

我们希望为客户带来统一的研发体验，并提供集成服务，其中包括Patch等专业资产，使我们的客户能够利用比以往任何时候都更广泛的功能集。”。

This strategic move follows Ginkgo's collaborations with Pfizer, based around the discovery of RNA-based drug candidates, with the aim of achieving efficient production, circularization, improved stability, and enhanced translation of each RNA construct. Ginkgo is also working with Sensible Biotechnologies to develop an in vivo microbial mRNA manufacturing platform..

这一战略举措是在银杏与辉瑞合作之后，围绕基于RNA的候选药物的发现，旨在实现高效生产，环化，提高稳定性和增强每个RNA构建体的翻译。银杏还与明智的生物技术合作，开发体内微生物mRNA制造平台。。

Additionally, Ginkgo announced the successful completion of a manufacturing optimization program with Biogen, redefining the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors. The collaboration achieved its goals of enhancing the AAV production titers of Biogen's gene therapy manufacturing processes..

此外，银杏宣布与Biogen成功完成了制造优化计划，重新定义了制造重组腺相关病毒（AAV）载体的行业标准。该合作实现了提高Biogen基因治疗制造过程中AAV生产滴度的目标。。

The addition of Patch's assets can help Ginkgo further expand its pipeline of gene therapy, cell therapy, and RNA programs and has the potential to immediately accelerate progress on current programs.

Patch资产的增加可以帮助银杏进一步扩大其基因治疗、细胞治疗和RNA项目的渠道，并有可能立即加速当前项目的进展。

JB Michel, CEO and co-founder of Patch Biosciences: 'Joining Ginkgo Bioworks represents an exciting step in our journey to engineer better genetic medicines. The shared vision and unique expertise of both teams can unlock new frontiers in programmable medicines, which we see as the future of medicine.

Patch Biosciences首席执行官兼联合创始人JB Michel说：“加入银杏生物工程（Ginkgo Bioworks）代表着我们在设计更好的基因药物的旅程中迈出了令人兴奋的一步。两个团队的共同愿景和独特专业知识可以打开可编程药物的新领域，我们将其视为医学的未来。

We are excited to contribute our AI/ML capabilities to the impressive Ginkgo platform, and look forward to engineering better genetic medicines for Ginkgo's customers in RNA therapeutics, gene therapy, and beyond.'.

我们很高兴为令人印象深刻的银杏平台贡献我们的AI/ML能力，并期待为银杏客户在RNA治疗，基因治疗等领域设计更好的基因药物。”。

Reach out to us at genetherapy@ginkgobioworks.com and learn more about Ginkgo's services in genetic medicines on our website:

联系我们genetherapy@ginkgobioworks.com并在我们的网站上了解更多有关银杏在基因药物方面的服务：

-   Gene Therapy Services

-基因治疗服务

-   Cell Therapy Services

-细胞治疗服务

-   RNA Therapeutics Services

-RNA治疗服务

About Ginkgo Bioworks

关于银杏生物制品

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats.

银杏生物工程（Ginkgo Bioworks）是细胞编程的领先水平平台，提供灵活的端到端服务，为食品和农业、制药、工业和特种化学品等不同市场的组织解决挑战。银杏的生物安全和公共卫生部门由银杏同心，正在建设全球生物安全基础设施，以增强政府、社区和公共卫生领导人预防、检测和应对各种生物威胁的能力。

For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn..

有关更多信息，请访问ginkgobioworks.com和concentricbygingo.com，阅读我们的博客，或通过社交媒体渠道关注我们，如X（@gingo和@ConcentricByGBW）、Instagram（@ginkgobioworks）、Threads（@ginkgobioworks）或LinkedIn。。

Forward-Looking Statements of Ginkgo Bioworks

银杏生物制品的前瞻性陈述

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the acquisition and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words 'believe,' 'can,' 'project,' 'potential,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions.

本新闻稿包含联邦证券法所指的某些前瞻性声明，包括有关收购和银杏细胞编程平台的能力和潜在成功的声明。这些前瞻性陈述通常由“相信”、“可以”、“项目”、“潜力”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将会”、“将会”、“将会”、“将会继续”、“可能的结果”以及类似的表述来识别。

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transa.

前瞻性陈述是基于当前预期和假设的关于未来事件的预测、预测和其他陈述，因此会受到风险和不确定性的影响。许多因素可能导致实际的未来事件与本新闻稿中的前瞻性声明存在重大差异，包括但不限于：（i）由于各种因素，包括银杏经营和计划经营的竞争性和高度监管行业的变化，竞争对手业绩的变化，银杏证券价格的波动，以及影响银杏业务的法律法规的变化，（ii）实施商业计划、预测和其他期望的能力，以及识别和实现额外商业机会的能力，（iii）使用合成生物学的产品需求下降的风险，（iv）被动监测计划和生物安全服务需求的不确定性，（v）生物安全行业的变化，包括技术进步、新兴竞争以及行业需求、标准和法规的演变，（vi）我们实现并购交易预期收益的能力。

GINKGO BIOWORKS INVESTOR CONTACT:

银杏生物工程投资者联系人：

investors@ginkgobioworks.com

investors@ginkgobioworks.com

GINKGO BIOWORKS MEDIA CONTACT:

银杏生物制品媒体联系方式：

press@ginkgobioworks.com

press@ginkgobioworks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-acquires-patch-biosciences-expanding-suite-of-genetic-medicine-capabilities-available-to-customers-302073671.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/ginkgo-bioworks-acquires-patch-biosciences-expanding-suite-of-genetic-medicine-capabilities-available-to-customers-302073671.html

SOURCE Ginkgo Bioworks

来源银杏生物制品

Company Codes: NYSE:DNA

公司代码：纽约证券交易所：DNA